biomed devic servic
look back fresh thought
head busi week med-tech
roll robust year med-tech outperform across nearli
everi subsector cap rang screen criteria look spent better part
advoc care stock pick sector valuat stretch histor
level ahead tradit choppi report period enter
high valuat remain front mind howev see mani reason stay
bullish underli market trend given continu new product cycl corpor tax
reform expect busi period
note provid comprehens updat nearli everi compani coverag
except entl nxtm pend take-out take
look perform screen may mean
roll valuat framework
updat favorit stock head
amongst large-cap continu favor snn remain opinion
one best posit respect product cycl industri trend near
 long term well run firm med-tech expect share momentum persist
snn equal strong cadenc new product expect
year investor final start pay attent robot solut navio
also highlight new ceo hire potenti catalyst investor
mid-cap space carri bullish view mid-tier spine player
 ye procedur trend soft howev last
year headwind year tailwind compani lap easi comp
across core us spine segment tandem robust new product cycl lastli
expect compani materi benefit us tax reform head head think
edg risk/reward standpoint given valuat room oper
leverag howev bullish set-up excelciusgp
robot long-term opportun within emerg technolog
lastli small-cap investor highlight turn-around potenti
opportun re-emerg share taker aesthet fda approv expect
earli remain overhang share howev like risk-reward
biomed devic servic
price close busi januari
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
biomed devic servic
what work dig number
follow page weve play around differ screen evalu
stock perform across med-tech given broad market strength
difficult screen discern group winner name almost
everi group sever winner said find fundament group
think help frame idea year
look market cap mid-cap medic devic name perform best
averag return follow close small-cap larg cap
analysi base market cap start sever name move
group follow stellar perform
term growth compani top growth quartil enter
project growth outperform peer annual stock
return
look ev/sal lowest cheapest valuat outperform specif
group compris stock ev/sal averag
annual return
ev/ebitda multipl similar outcom lowest ev/ebitda multipl
meaning outperform group specif name enter
ev/ebitda return averag
lastli look price-to-earnings indic pay expens p/e would
outperform rest group group stock price-to-earnings
return averag
base begin datacurr price-to-earnings current stock performancelarg cap cap work growth valuationgrowthev/salesp/eev/ebitdamarket cap what work look valuat ev/sal
 least expens tabl show return own posit expens stock med-tech
year ev/sal basi valuat base revenu estim convers similar basket cheapest stock med-tech
biomed devic servic
strategi head least expens stock ev/sal basi today
companytickermarket group ent ev/revenu valuationtop expens ev/rev top least expens ev/rev intuit exclud h/l exclud h/l ev/sal least expensivetop expensivetop least expensivecompanytickermarket cap stock performancebeg year salestoday salescompanytickermarket cap today beg year salestoday stock perform what work look valuat ev/ebitda
 least expens tabl show return own posit expens stock med-tech
year ev/ebitda basi valuat base ebitda estim convers similar basket cheapest stock med-tech
biomed devic servic
strategi head least expens stock ev/ebitda basi today
medic group exclud h/l exclud h/l ev/ebitda least expensivetop expensivetop least expensivecompanytickermarket cap today beg year ebitdatoday stock performancecompanytickermarket cap today beg year ebitdatoday stock performancecompanytickermarket cap today ev/ebitda cap today ev/ebitda group ev/ebitda valuationtop expens ev/ebitda top least expens ev/ebitda what work look valuat price-to-earnings
 least expens tabl show return own posit expens stock med-tech
year price-to-earnings basi valuat base price-to-earnings estim convers similar basket cheapest stock med-tech
biomed devic servic
strategi head least expens stock price-to-earnings today
 corp exclud h/l exclud h/l cap today beg year epstoday stock price-to-earnings least expensivetop expensivetop least expensivecompanytickermarket cap today beg year epstoday stock performancecompanycompanytickermarket cap today price-to-earnings cap today price-to-earnings price-to-earnings valuationtop expens price-to-earnings top least expens price-to-earnings what work look sale growth
fastest slowest grower tabl show return own posit fastest project grower
revenu growth convers similar basket slowest grower med-tech
biomed devic servic
strategi head fastest slowest grower project revenu growth today
ceru exclud h/l exclud h/l stock enu growth fastest slowesttop fastest growerstop slowest growerscompanytickermarket stock project growth todayproject current companytickermarket project growth todayproject current companytickermarket growthcompanytickermarket enu growthtop fastest growerstop slowest grower what work look prior year share perform
best worst stock perform tabl show return own posit best stock perform base
return convers similar basket worst perform stock med-tech
biomed devic servic
strategi head best worst stock perform
companytickermarket price performancecompanytickermarket price ent group worst perform return return ent corp exclud h/l exclud h/l perform best worst perform best stock returnstop worst stock returnscompanytickermarket stock stock performancecompanytickermarket stock stock perform recap high level thought implic
biomed devic servic
theme perspect remain convinc
highlight past sever
year med-tech acceler
lead consolid space
previous seen
reinforc thesi saw nearli
entir aesthet sector acquir
interest dynam buyer
willing take deal dilut
near-term indic potenti bigger
appetit view compel long-
acquisit novadaq entellu exampl
expect dilut
first year post acquisit
respect coverag said goodby
small cap name year includ zltq
nxtm entl
look
thesi remain intact pauciti
expect small/mid cap compani
continu view attract growth
expect corpor tax reform
repatri ou cash potenti catalyst
acceler
like target coverag
targetacquirordateimpli evttm revenueev ttm salesreshap medic inc enteromed lab inc sientra medic ltd apax partner israel inc holog aesthet inc allergan inc tpg capit medic inc smith nephew synth prodisc assetscentinel spine inc nuvas element inc amendia spine inc depuy synth medic inc bd inc teleflex medic inc freseniu medic inc entellu medic inc royal inc bard inc becton dickinson monitor recoverycardin health codman neurosurgeryintegra scienc inc integra denot pend notabl medic devic acquisitionsaestheticsoth relev aortho spine valuat financi medic technolog larg cap billion
next four page weve highlight chang estim valuat share price relev comp group cours
biomed devic servic
 exclud median ep exclud lp changesacquir compani price last day tradingmed devic universebas jan larg market cap billion million except per share data compani nametickermarket cap ep valuat financi medic technolog mid cap billion billion
biomed devic servic
inc corp exclud median ep exclud lp changesacquir compani price last day tradingmed devic universebas jan mid market cap billion billion million except per share epscompani nametickermarket cap ep valuat financi medic technolog small cap
biomed devic servic
medic ent group exclud median ep exclud lp changesacquir compani price last day tradingmed devic universebas jan small market cap billion million million except per share data compani nametickermarket cap ep valuat financi medic technolog high growth
biomed devic servic
exclud median ep exclud lp changesmed devic universebas jan estim growth compani nametickermarket cap ep biomed devic servic
canaccord genuiti medic devic team recent publish depth med-tech schedul inclus key tradeshow forum
symposium canaccord event link
highlight confer advis client pay close attent specif event cover relev sector
orthoped obes diabet dialysi neuro ent aesthet
attend mani event often schedul meet around keep eye invit
kyle orthoped obes diabet dialysi neurotechnolog ent aestheticsorganizationacronymdatescitystatevenueint advanc treatment diabetesattdfebruari austria-austria centreamerican academi dermatologyaadfebruari diegocasan diego convent centercanaccord genuiti musculoskelet conference-march orleanslasheraton new orlean american academi orthoped surgeonsaaosmarch orleanslamori convent centeramerican societi laser medicin surgeryaslmsapril anatolesymposium advanc wound wound heal soc sawc-whsapril convent centeramerican societi aesthet surgeryasapsapril may york citynyjacob javit centeramerican associ neurolog surgeonsaansapril may orleanslaernest morial convent centercurr concept replac springccjrmay vegasnvaria citi centeramerican diabet associationadajun countri convent centeramerican associ diabet educatorsaadeaugust baltimorenorth american spine societynassseptemb anglescatbdamerican societi surgeonsaspssept oct grandcongress neurolog surgeonscnsoctob houstontxgeorg brown convent centeramerican academi otolaryngologistsaao-hnsoctob world congress centeramerican societi nephrologyasnoctob diegocasan diego convent centersymposium advanc wound sawc novemb vegasnvcaesar la vegasamerican societi metabol bariatr surgeryasmbsnovemb citi centercanaccord genuiti medic nolog diagnost forum-novemb yorknywestin grand centralcurr concept replac winterccjrdecemb regenc grand cypress biomed devic servic
canaccord genuiti event
venu detail public/priv compani focus orthopedics/trauma/sportsmed/spine/orthobiolog
detail public/priv compani focus medic technolog diagnost
canaccord genuiti catalyst calendar keep eye event
biomed devic servic
companyeventtimingsignificanceintersect entsal forc expans sale forc adcom/pma approv epxect commerci launch month follow adcom panelsenseonicseu launch eversens eversens sensor life day fda pma approv new manufactur y/i growth breast augment reconstructurion repres cg y/i growth entsinuva commerci w/ launch management build best practic cg revenu estimateconformiscomplet integr broadpeak add gross maringssmith nephewintegr rotat integr provid act tailwind sport medicin entellu ent capabilitit strong asset dilut adj ep accret thereafterinsuletassum direct oper repres estim ou transit drive ou asp annual calibr ww launch devic prioriti dictat pma- file management may delay launch skip dash expect meaning product cycl given new featuresobalonpma- approv new inflat navig safer placement balloon expect support continu market adoptionhistogenicsneocart pivot trial data support fda submiss neocart eventu pma approv commerci launch cg estim launch given recent timelin slip us cg estimatesful breast implant inventori estim full inventori avail allow get back offens breast aug conformiscommerci launch itot hip market opportun hip replac usintersect entreimburs sinuva assign uniqu j-code like toward end year key next wave adopt acquisit acquisit nxtm trade meaning discount given regulatori concern share concernszimmerpersona revis ww portfolio gap persona kneeszimmerpersona cementless tibia ww portfolio gap persona kneeszimmerrosa robot knee beta robot platform combat success competitior mako navio potenti stem share losszimmerrosa robot spine/brain rosa acquisit meaning robot calibr ww product launch close gap new competitior support continu growthrewalkrestor soft-suit us beta toward unlock patient us stroke market smith nephewceo succes ceo succes plan follow upcom retir ceo olivi bohuon biomed devic servic
recap thought head
robot everywher industri investor attent robot surgeri significantli acceler
move full commerci launch mako total knee applic view valu proposit
robot assist surgeri yet fulli articul total joint howev discount earli stage
market limit clinic data abil hospit leverag system compet patient volum
market regardless view technolog natur extens broader industri shift toward
improv fit accuraci align implant benefit current provid via
altern technolog remain seen whether increment benefit robot platform capabl
offset increas cost complex regardless stryker mako smith nephew navio
demonstr physicians/hospit genuin interest technolog expect continu
procedur shift outpati set saw continu momentum weve seen build
past three year shift procedur outpati set specif environ increas
cost/pric headwind procedur normal reserv inpati set shift less acut
set whenev possibl view shift outpati set acceler support
remov tka inpati list
shift episodic/bundl reimburs despit voluntari particip cjr believ cat
bag respect shift momentum away fee-for-servic view physician hospit
manufactur econom reward healthier patient rather procedur throughput
coupl emerg big data analyt expect see persist improv patient
outcom well price transpar echo broader industri introduc new technolog
focu procedur effici cost improv expect continu focu decreas
cost improv clinic outcom beyond
import catalyst
increas competit robot surgeri navig
snn navio enter broader market releas
zimmer robot platform rosa slate
beta launch bring competit stryker
mako think import year
solidifi posit advanc technolog
first year reimburs outpati tka
final opp rule remov tka
inpatient-onli list result look sign
meaning outpati growth
industri take advantag trend
shift episod bundl continu
cjr rule voluntari expect privat
insur implement episod bundl total joint
normal competit total joint
zimmer donat share year deal
manufactur issu market look
like offens
still await result estim us knee hip market grew y/i support healthi procedur volum off-set price pressur
view snn primari share taker total joint larg expens compani leverag robot
look expect continu donat share result manufactur constraint
recap thought head
weak procedur volum head scratcher finish high note robust sluggish
us procedur volum ytd caught industri investor surpris nass year met
public privat spine compani multipl physician histor weve abl use dilig way
identifi emerg trend like chang insur requir acceler price pressur unexpect procedur
trend dilig year fail provid evid consist underli driver would explain y/i
declin procedur growth year estim channel check indic smoke
gun procedur weak lead us believ slowdown confluenc price reimburs
increas season move look earli sign market rebound
trough potenti act tailwind spine player
diversifi capit eye robot navig robotic-assist surgeri emerg key market
theme orthoped past year investor focu center util total joint replac said
felt mark turn point regard applic broader spine market endors major
industri player piqu interest industri player new product launch
lessray globu excelsiusgp squar focus industri investor attent capit offer
major spine player channel check indic high surgeon/hospit demand product expect
solidifi entranc spine market bring innov expect launch
updat instrument mazorx zimmer guid launch rosa brain/spin robot
increas focu value-bas care set year spine confer heavili focus patient
outcom day bundl payment scheme cost-effect new technolog bottom line
environ increas cost/pric headwind procedur normal reserv inpati set
shift less acut set whenev possibl due reimburs risk/benefit procedur techniqu
improv medic technolog new trend believ gain mindshar accept
spine commun expect continu adopt
biomed devic servic
import catalyst
return stabl procedur volum
restor confid sector
follow year weak volum
think industri like need rebound
support posit sentiment spine player
banner year expans
capit equip inflect point
product ramp full commerci launch
earli feedback use capit equip
good critic year whether
product evolut spine
space drive util anoth excit
line ytd result estim us spine market end larg flat y/i modestli rebound y/i growth
within cover name expect strong us result share take market
share expect head one busiest healthcar week year
biomed devic servic
rev epsstryk bia estim continu share gain ortho support driven mako well strength endoscopi expect guidanc in-lin zimmer yessal ep in-lin slightli consensu look updat manufactur issu expect full year guidanc smith expect pre-announcedexcom solid result conserv guid account libr headwind expect materi updat roadmap timelinesglobu medic see upsid us momentum robot expect robot placement pre-announc said would surpris see rev ahead consensu conserv guid upsid conserv estim look anoth conserv guid posit compani beat/rais storynxstag expect pre-announc pend acquisit freseniusintersect ent upsid estim expect conserv guidanc heel sinuva approv year establish reimburs entellu expect pre-announc pend acquisit expect pre-announcesientra expect expect pre-announceconformi preced surpris see in-lin conv guidanc expect pre-announcerewalk expect pre-announceexpect preliminari result cg commentsexpect pre-announc present time pt cg estimatecompani nametickerratingpric targetmarket cap biomed devic servic
thought cover compani hold pt
canaccord genuiti take-away
canaccord genuiti thought
challeng year new ceo reshap strategi ceo mark augusti join compani
cours restructur commerci team
implement strateg chang aim drive sustain top-lin momentum
chang multipl level commerci team caus near-term disrupt y/i
sale growth howev success growth initi begin show
product improv
german reimburs chang drag chang partial knee
reimburs code germani went effect jan estim
impact y/i growth
remain headwind posit momentum slower top-lin growth impact
y/i gm expans gm guidanc adjust
post result said cost save in-sourc initi
track top-end rang guidanc
cg thought head
commerci execut manag guid quarter turn-around process
commerci organ suggest earli sign momentum becom
measur despit season look new commerci initi
leadership new rep corpor account team begin show y/i product
gm expans gm leverag pivot share perform initi
includ insourc tibial tray complet insourc poli insert cr complet
ps broadpeak acquisit improv design/labor
effici current forecast
new product new product launch queu includ
improv exist iuni itot product well ihip
expect enter beta launch
financ overhang month runway base exist cash
access debt howev expect financ event reliev
signific share overhang end cash model
cash burn
new product launch
includ iuni itot ihip
clinic data set aao aahk
integr broadpeak manufactur
expect drive
improv
relev discuss topic manag
sale rep product expect vs
new product launch cadenc
strategi outpati total joint market
updat strategi ou geographi
financ strategi timelin
gm expans cadenc scale vs insourc vs cost reduct
stack robot platform econom clinic result
develop manufactur commerci custom orthoped
implant util patient ct scan proprietari algorithm compani
manufactur custom implant combin patient-specif instrument
first commerci knee expand cruciat retain
cr total knee recent posterior stabil ps knee
price high/low perform capit valu daili volum equival posit interest float snapshot biomed devic servic
thought cover compani inc buy pt
canaccord genuiti take-away
canaccord genuiti thought
cgm competit market us abbott libr secur pma approv
libr overhang fundament via sentiment libr certainli
surprisingli strong label insulin dose calibr day sensor
coupl aggress commerci strategi via pharmaci channel
sensor rais signific concern investor regard
near-term metric like new patient growth exist patient attrit price
medicar remain untap opportun competit despit
posit coverag announc earli penetr market
patient slow uncertain coverag requir oner
patient onboard process limit patient onboard dexcom
note expect on-board signific portion patient wait list
signific new patient growth expect said earli
abbott announc receiv approv libr like
creat increas competit popul throughout
ou market growth reinforc global opportun cgm deliv
y/i growth ytd ou driven improv reimburs particularli germani
impact new patient growth said believ continu grow
mid/high-teen beyond support view technolog
superior product pipelin pediatr uptak although libr approv make
harder ou strength model y/i revenu growth
consensu
ou growth driver expect except growth continu
improv payor coverag market access provid ampl new patient opportun
ou importantli ou growth come region compet
directli libr offer earli sign libr potenti market-expand effect
new product verili cant come soon enough view
best class technolog robust product pipelin includ verili
product new product key offset libr growth maintain
posit innov eye physician patient look updat
no-calibr product expect commerci launch occur
late
uncertain commit launch
no-calibr
previous guid verili launch
timelin updat
no-cal top prioriti dictat
clinic data set expect attd ada
improv reimburs germani exit
cover live
relev discuss topic manag
new product cadenc includ cal no-cal verili
commerci access plan pharmaci benefit channel
opex expect given competit us market
medium term market opportun cgm technolog market
opportun grow broader diabet tech compani
medic devic compani focus design develop
commerci continu glucos monitor system ambulatori use
peopl diabet use health care provid hospit
treatment diabet non-diabet patient
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani globu medic buy pt
canaccord genuiti take-away
canaccord genuiti thought
transit year us core spine market somewhat insul
unexpect slowdown us spine market given lap soft y/i
comp follow distribut turnov howev pace rebound us
product ramp slower expect regardless show strong
momentum new product flow sale rep hire
new product get credit deserv final launch timelin key
emerg technolog robot trauma product slip quarter
surpris see impact investor sentiment particularli
modest guidanc regulatori approv secur commerci
team place believ long-term opportun emerg technolog remain
underappreci investor
ou exceed expect ou growth significantli outperform
expect track vs estim start year
integr alphatec ou busi progress quicker expect
channel disrupt overlap distributor minim
emerg technolog focu launch excelsiusgp system
remain key focu head manag guid month
sale process capit equip space suggest momentum system
placement acceler set upsid estim
view excelsiusgp innov compel robot spine
surgeri platform expect leverag foundat spine expand
addit orthoped market next sever year
ou growth expect ou growth remain robust secur
regulatori approv legaci product launch key technolog
market like japan current model y/i growth ou see
upsid potenti low- mid-teen
tax reform regardless nuanc tax plan shake see
materi beneficiari current model tax-rat go forward basi
point upsid ep estim us tax-rat said
expect manag like reinvest portion tax save back
busi similar happen med-tech tax suspens
robot launch market tenur launch
ramp throughout
product flow addit sale forc
tax reform tax payer
revenu us current
relev discuss topic manag
expect sale rep product improv driven
expect increas competit expand cage market impact
price futur growth disrupt technolog
emerg technolog contribut mix robot vs trauma
next emerg technolog trauma robot
ou legaci product current approv japan
fulli transit product
impact tax reform much realiz vs reinvest
globu medic medic devic compani focus exclus design
develop commerci product promot heal patient
orthoped disord includ spine trauma
price perform capit valu daili volum equival posit interest medic snapshot biomed devic servic
thought cover compani histogen hsgx buy pt
canaccord genuiti take-away
canaccord genuiti thought
neocart enrol complet phase trial complet enrol
expect remain track data readout fda submiss
remind trial enrol patient across xx clinic site evalu
safeti efficaci neocart vs standard care microfractur
clariti regulatori path japan histogen reach agreement
japan pmda regard regulatori pathway japanes market revolv
around small one-year trial compar neocart microfractur treatment
trial supplement us phase clinic trial data well
support document fda approv
expans japan late histogen announc
enter agreement medinet develop commerci
neocart japan importantli agreement includ total mileston
payment includ up-front addit mileston payment
expect royalti payment base revenu
mileston follow commerci neocart japan
phase data read-out mid year key event clearli pivot trial data
ph neocart trial last patient complet endpoint june
top-lin data expect shortli thereaft like late july/august note major
academ confer american academi sport medicin aossm fall
similar timelin may make sens venu showcas data late-break
aossm take place juli san diego
expect financ event expect histogen pursu equiti financ event
follow posit clinic data result time-frame current
model rais would support compani fda approv
well earli phase build direct sale team commerci
launch us
ph data expect
financ event
relev discuss topic manag
neocart compar exist product market current
develop expect launch
walk japanes partnership medinet breakdown total
expect buildout us commerci channel
cash burn trend come month top-lin data fda
updat timelin single-cel neocart product catalyst
investor expect
histogen clinical-stag medic devic compani concentr develop
tissu product musculoskelet segment orthoped market
histogen first product neocart current ph clinic trial tissu implant
intend treat cartilag damag knee use patient cartilag cell
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani insulet corp buy pt
canaccord genuiti take-away
canaccord genuiti thought
posit consolid industri jnj/anima decis exit insulin
anima us growth anima market exit potenti benefit way
pump industri chang competit landscap elimin
player market share unless tandem player abl materi
improv margin profil cash burn believ industri head duopoli
new patient adopt defin tube vs patch pump
ou growth engin direct oper horizon year come
model y/i growth fast forward month
estim call y/i driven robust patient adopt franc
dash impress ada ada coming-out parti next gener omnipod
bring new user interfac bluetooth connect clinician feedback
exceedingli posit new devic someth believ help drive increas
patient demand next month
execut gross margin consist execut manufactur shift sea
vs air freight track improv y/i vs
model start
decreas competit new patient start convers opportun
legaci anima patient patient convers draw signific investor
attent view decreas competit new patient biggest opportun
amina exit elimin key player competit pediatr
patient expect momentum build throughout remind investor
natur podd busi model diminish near-term upsid potenti new
patient addit typic account annual revenu
current model y/i growth us howev see upsid
rang new patient adopt convers acceler
go direct ou view decis go direct ou start solid
long-term valu driver secur global right omnipod deliv
improv annual transit ou major focu investor
given potenti channel disrupt howev view agreement
ypsome includ mileston payment base patient retent
help off-set near-term risk
clinic data set expect attd ada
dtm pre-pivot trial horizon ap
relev discuss topic manag
expect sale rep product anima exit dash new product launch
time updat cms/medicar approv
mileston expect direct oper
plan expand geographi beyond eu
gm expans shift ou
expens invest requir ou op
involv develop manufactur market novel insulin
infus system diabet omnipod dispos insulin pump
discret wireless allow improv qualiti life
activ lifestyl want encumb cathet requir
commerci avail insulin pump system
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani intersect ent buy pt
canaccord genuiti take-away
canaccord genuiti thought
propel contour market expansionari potenti one pushback contour
launch potenti cannib exist propel util instead dilig
report result indic uniqu shape strong clinic outcom
led increas util frontal sinu util trend show
momentum order account increas q/q
commerci execut back track commerci execut challeng
reimburs chang repres signific overhang investor
sentiment start said banner year execut
demonstr strength updat commerci team sale develop
program junior rep initi sale headcount increas
manag guid addit increas
sinuva clinic data reinforc revis opportun full data resolv ii trial
releas met co-primari endpoint well four pre-
specifi secondari efficaci endpoint full detail resolv ii sinuva
sinuva remain focu next month suspect largest challeng
manag like keep investor expect growth ground
realiti given product launch expand address market includ
patient continu experi symptom post fess procedur
current model sinuva revenu vs market oppti
annual expect undertak control commerci
roll-out train sale forc physician navig oner reimburs
process coverag polici place link deep dive sinuva
propel remain earli stage adopt contour continu driver despit
launch continu believ propel remain earli stage market
adopt current estim propel penetr fess procedur
expect contour remain signific growth driver
adopt broader account base account order
vs broader account base
sale forc expans
sinuva us commerci launch
public sinuva pivot trial data
reimburs process j-code
reimburs sinuva
relev discuss topic manag
expect sale rep product improv sinuva launch
propel util vari across differ us geographi biggest driver
util trend
oper spend trend support commerci launch sinuva
walk mileston pathway toward reimburs sinuva
think sinuva first year rel product launch
meaning chang reimburs polici follow shift
bundl price ent procedur
plan ou commerci next year
intersect ent commercial-stag medic technolog compani focus
provid therapeut solut patient ear nose throat condit
compani initi focu treatment chronic sinus use
steroid-releas resorb implant provid local deliveri steroid
directli sinus help reliev symptom chronic sinus
price perform capit valu daili volum equival posit interest ent snapshot biomed devic servic
thought cover compani buy pt
canaccord genuiti take-away
canaccord genuiti thought
sluggish year us core spine market finish high note
robust sluggish us procedur volum caught industri investor
surpris research indic smoke gun procedur weak lead us
believ slowdown confluenc price reimburs increas
season regardless model growth y/i us spinal
hardwar vs time last year
diversifi capit lessray counter procedur weak surg
investor interest nuva lessray system believ remain
underappreci simpli put lessray bring solut fundament problem
mi physician impact result howev mute control launch
rental/leas model believ mask underli unit
robust line-up new product mani investor remain focus lessray
also highlight broader pipelin implant/procedur product innov
robust seen sever year specif launch
modulu xlif print titanium cage relin trauma small statur new
single-posit later procedur techniqu current model growth us
spinal hardwar see upsid closer y/i
lessray view lessray compel opportun expect investor
sentiment increas time expect build
foundat includ futur technolog like robot arm navig
integr broad suit procedur innov solut facilit
continu share take
manag turnov investor sentiment took anoth hit compani made
ou growth expect ou growth remain robust continu take share
sever manag chang mid-year turnov rais eyebrow believ
departur key investor face role cfo vice-president financ exacerb investor
concern result
key countri like japan current model y/i growth ou
tax reform issu preliminari comment suggest tax rate low-
rang converg rate futur year
product improv competit rep
hire come line next
relev discuss topic manag
expect sale rep product improv driven
lessray expect contribut mix rental vs outright purchas
expect next version lessray overal capit equip
commit y/i margin improv
impact tax reform much realiz vs reinvest
expect us procedur trend enter anoth complet
addit insight slowdown
medic devic compani focus design develop
market product surgic treatment spine orthoped disord
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani obalon obln buy pt
canaccord genuiti take-away
canaccord genuiti thought
strong execut first year us market first year us
commerci track significantli outperform initi expect
specif model us revenu vs point
last year underli commerci momentum grown q/q even hurrican
impact date manag highlight q/q improv nearli
oper metric includ physician addit re-ord new patient interest
new product lower barrier entri expect obalon launch updat
balloon system believ meaning lower barrier physician
adopt specif obalon file pma- approv novel navig system
obalon nt elimin need x-ray place balloon new
inflat system obalon touch inflat autom process balloon
set-up manag provid launch timelin howev believ pma-
regulatori process point market launch
grow instal base physician user obalon faster expect fda approv
posit compani head-start commerci activ physician
target sale rep educ market initi januari launch
translat strong new account addit math translat
instal base physician user clinic site
investor still wait market valid despit outperform us commerci
expect investor sentiment larg driven earli stage
emerg aesthetic/weight-loss market segment think fda dear-doctor letter
concern liquid fill balloon remain neg overhang broader
intragastr balloon space market see show stori
sonobello agreement offer upsid obln announc agreement
offer obalon system sonobello practic across us someth view
strong lead indic momentum key aesthet channel sonobello one
countri largest cosmet surgeri practic locat board-
certifi plastic surgeon detail agreement thu far scant
believ sonobello broad geograph reach exist patient flow market
capabl offer opportun robust growth beyond
ou growth expect ou growth rebound re-ord rate normal
follow launch balloon system
world clinic data obalon
launch new product includ navig
system inflat devic
procedur adopt sonobello
sale rep hire new geographi
relev discuss topic manag
expect sale rep hire underli product metric like same-
new product cadenc beyond
scale broader dtc advertis campaign make sens
expect see larg stock order sonobello come line
level commerci traction allow financi guidanc
primarili gain market share competit convers expand
addit competit product horizon
obalon medic devic compani focus treatment obes
overweight patient obalon balloon system first swallow gas-fil
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani rewalk robot rwlk buy pt
canaccord genuiti take-away
canaccord genuiti thought
underli patient demand problem system placement
expect finish year vs contrari
inconsist q/q financi result rewalk patient demand continu grow
steadi rate backlog increas q/q pend commerci
claim repres
posit coverag decis germani rewalk secur two posit coverag
decis germani repres cover live specif
rewalk receiv posit coverag decis german nation social accid
insur dguv cover live well barmer privat insur cover
us reimburs remain challeng despit manag character
posit discuss us payor rewalk achiev goal posit us
payor decis polici review payer includ round question
initi expect slip
reimburs remain limit factor big question
addit reimburs win occur increas coverag posit
impact financi result coverag decis encourag
view posit decis major us payor key catalyst drive share
appreci said even posit coverag expect take addit
month claim process patient pipelin translat system
placement revenu
restor offer anoth leg growth rewalk continu make progress
develop restor softsuit exoskeleton system design stroke patient
call manag highlight begin trial
site assess safeti efficaci soft-suit system guid
launch eu launch us soft-suit system
expect cost price manag think allow support system
clinic data restor soft-suit studi
earli clinic data va studi
posit coverag decis us payor
relev discuss topic manag
updat timelin posit coverag decis us payor ou payor
long take posit coverag decis impact top-lin growth metric
much patient backlog expect cover insur
polici
commerci plan restor differ rewalk exoskeleton
plan financ compani move forward
rewalk robot develop manufactur market wearabl robot exoskeleton
individu spinal cord injuri
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani senseon buy pt
canaccord genuiti take-away
canaccord genuiti thought
ou race solid year first full year
us approv key event timelin slip
eversens commerci europ compani transit control
launch countri sweden germani broader commerci launch across
europ track exit market access countri
expand relationship roch big year senss partnership
roch roch expand ou distribut agreement includ
europ ex scandanavia compani also invest
financ sharehold ownership posit
us regulatori timelin slip call push back guidanc
us fda approv eversens earli specif manag
note question/answ process took longer expect howev compani
expect answer fda outstand question would like
lead fda adcom panel
manag reiter confid regulatori timelin
approval/commerci guid expect adcom
panel meet howev knowledg noth schedul
yet ou commerci continu gain momentum believ time us
approv process commerci earli summer june/juli key
drive share momentum current model us revenu
come
long-term pipelin progress dilig suggest devic suffici
garner foothold us market howev subsequ approv
devic eversens xl signific driver us physician patient adopt xl
current earli launch process ou expect pursu us
regulatori process shortli approv devic
us fda adcom panel meet
us regulatori approv
us commerci launch
clinic data canadian trial eversens
pediatr patient
europ launch eversens xl
expans addit ou market
relev discuss topic manag
updat timelin us regulatori decis eversens
plan build us commerci team
updat pipelin subsequ time
addit countri expect launch eversens
strategi financ event move forward
senseon medic technolog compani focus design develop
commerci glucos monitor system intend enabl
peopl diabet confid live live eas util fluoresc
sens technolog system design first fulli
implant continu glucos monitor system highli accur stabl
throughout long sensor life day
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani buy pt
canaccord genuiti take-away
canaccord genuiti thought
us regulatori timelin slip call updat guidanc
us approv key event timelin approv slip
pma- approv new manufactur facil initi built
month buffer guidanc inspect took place two month later
expect push timelin note manag
confid question receiv fda administr natur
would requir addit data updat expect accordingli
transit broader aesthet platform growth began demonstr
strategi transit broader aesthet platform via tuck-in
past month specif scar manag biocorneum breast
despit on-going suppli constraint core breast implant
mirimar next leg growth mileston acquisit mirimar add
differenti asset open tradit capital/consum aesthet devic
market hyperhidrosi believ repres market opportun
manag reiter plan build inventori risk ahead fda approv
maintain key commerci timelin continu model gradual
top-lin ramp new inventori rout key custom safeti stock
replenish follow q/q growth inventori level support
new custom convers model y/i growth breast implant
revenu
mirimar like stori outlin robust plan reinvent commerci
strategi treatment protocol invest sale market channel
believ drive acceler sale momentum end miramar
new sale leadership plan nearli doubl capit consum sale
team near term product side expect roll new procedur
templat system user interfac anesthesia protocol offer streamlin
treatment process improv patient comfort model revenu
come expect commerci chang take
month translat top-lin result
us fda approv new manufactur facil
full breast implant inventori avail
relev discuss topic manag
plan build us commerci team legaci
breast/recon busi well mirimar
updat timelin us regulatori approv new vesta manufactur
quickli anticip abl recaptur histor user
import chang make mirimar commerci
 opportun make sens exist sale channel
medic aesthet compani focus develop product enhanc
body-imag improv self-esteem restor confid seintra core focu
breast augment market util high-strength cohes high-
strength cohes hsc silicon gel breast implant long term
posit becom global aesthet compani via expand product portfolio
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani smith nephew snn buy pt
canaccord genuiti take-away
canaccord genuiti thought
track turnaround year first glace revenu growth estim
appear lower end large-cap med-tech highlight strong rebound
simpli put snn transit
protract period corpor restructur believ show
abil focu commerci execut deliv acceler earn growth
navio start line growth snn acquir navio howev total
knee applic beta-launch dilig physician
user suggest grow physician/hospit interest help part big market
push syk/mako believ potenti acceler capit
placement well knee unit growth beyond point highlight
solid global knee growth y/i come tough
comp y/i vs
anoth round cost save expect result call manag note
evalu opportun area improv reduc overal
oper expens move forward specif manag believ reduc
ineffici suppli chain optim manufactur decreas
invest new support system importantli unlik previou restructur
program manag note futur program impact
commerci organ top-lin growth look result call
februari detail note increas convict abil snn
deliv acceler ep growth
solid line-up new product snn cusp sever new product
cycl across key segment includ knee navio bcr journey ii sport medicin
new ceo may share catalyst current ceo olivi buhuon announc intent
retir offer view opportun improv investor
sentiment leadership chang year
broad commerci roll-out bi-cruci retain
journey ii includ navio platform
integr rotat medic
announc manag success plan
ceo olivi bohuon expect retir
announc detail regard new
cost save initi expect call
relev discuss topic manag
expect navio contribut top-lin growth
navio capabl drive surgeon convers snn implant system
investor view top-lin growth move forward mid/high-single-digit
expect us corpor tax reform impact much benefit
expect realiz vs reinvest
snn appetit weight tuck-in transform deal
investor feel confid top-lin growth impact anoth
smith nephew global develop medic devic orthoped
wound care market compani top-fiv player total joint replac
trauma wound care market
price perform capit valu daili volum equival posit interest floatnasmith nephew snapshot biomed devic servic
thought cover compani corp buy pt
canaccord genuiti take-away
canaccord genuiti thought
anoth stellar year track report anoth year stellar growth
orthoped medsurg outperform estim new product launch
strong commerci execut deliv market share gain key segment
knee trauma endoscopi someth believ persist move forward
mako play durabl growth driver undeni mako skeptic
come view execut except system placement
outpac expect impact pace grown
util total knee procedur perform sinc launch
came q/q vs
shi away alway one activ strateg
buyer med-tech howev one interest aspect
syk willing take dilut acquisit novadaq entellu indic
compani bigger appetit view long-term valu driver
continu share take orthoped shown y/i share gain knee sinc
launch cementless system cementless system clear
use mako platform expect on-going share gain persist
new physician trial adopt technolog believ
leverag product innov mako placement drive continu
halo mako custom share take adjac orthoped market segment
 flow busi unit busi
perspect spend combin acquir novadaq medsurg
vexim neurotech/spin entellu medsurg neurotech view
acquisit posit given broad set differenti product acquisit
bring syk histor strong track record integr tuck-in best-in-
class commerci channel yet add vexim entellu revenu
estim expect potenti drive top-lin growth
expect activ increas heel corpor tax reform
continu commerci roll-out mako
commerci launch cementless tka mako
complet integr novadaq acquisit
complet entellu acquisit integr
relev discuss topic manag
expect mako contribut top-lin growth
expect major mako system upgrad tka
would character syk appetit chang
recent tax reform
expect us corpor tax reform impact much benefit
expect realiz vs reinvest
competit robot surgeri market expect materi chang
snn navio broadli releas bring rosa market
one world lead medic technolog compani broad
product portfolio includ implant use joint replac trauma spinal
surgeri surgic equip surgic navig system endoscop
commun system patient handl emerg medic equip
medic devic product use varieti medic specialti
price perform capit valu daili volum equival posit interest snapshot biomed devic servic
thought cover compani zimmer biomet hold pt
canaccord genuiti take-away
canaccord genuiti thought
inventori suppli issu persist investor enter expect
supply/manufactur issu would allevi mid-year allow return
competit share take instead oper issu sever
expect investor head time frame
constraint eas
anoth tough year inventori constraint key total joint product line
limit zimmer abil fulfil custom demand throughout translat
anoth year share loss core hip/knee/trauma/sport market segment
ceo turnov given slow top-lin growth surpris see turnov
ceo particularli given protract period slow growth integr misstep
month post biomet merger us difficult integr process
subsequ manufacturing/suppli issu effect zimmer growth profil
signal clear need structur cultur chang throughout compani
sentiment revolv around new manag view hire new ceo bryan
hanson formerli evp presid medtron minim therapi group
posit catalyst share said share may get lift
announc new ceo believ top-lin growth key unlock
sharehold valu requir overcom operational/manufactur issu
well align commerci organ -- expect take
fulli month resolv weigh margin/earn growth least
new product key albeit heavili weight investor saw first sign
product new product front clearanc stemless
shoulder late said highlight backlog new product deck
commerci launch includ persona tm cementless tibial compon
guidanc estim conserv given hire new ceo took place
late expect full guidanc next week said
think manag take opportun set conserv guidanc
revenu rang y/i pro forma ep flat
new ceo bryan hanson like implement
strateg oper chang
relev discuss topic manag
investor think pace scale strateg oper
chang cours
would character zbh appetit chang
recent tax reform
like buyer seller perspect
expect us corpor tax reform impact much benefit
expect realiz vs reinvest
firm product launch timelin key product launch
impact supply/manufactur issu take longer expect remedi
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
price perform capit valu daili volum equival posit interest biomet snapshot biomed devic servic
includ appendix follow
chang price target
copi comp tabl
short interest chart med-tech univers
chang price target roll multipl
biomed devic servic
stryker earn lower multipl earn adjust multipl earn still base multipledexcom revenu adjust multipl medic earn adjust multipl revenu adjust multipl earn ebitda adjust multipl chang price target base acquisit priceintersect ent revenu still base multipleentellu chang price target base acquisit chang price target still base sale discount presentsientra revenu adjust multipl multipl still base sale discount presentconformi revenu adjust multipl chang price target still base sale discount presentrewalk price targetcompani nametickerratingold price target canaccord genuiti med-tech coverag overview
biomed devic servic
short-term trade pricepric targetmkt cap p/eev/salesgmcurr thought best large-cap space new product cycl continu mako capit share loss smith nephew plc sponsor portfolio support share gain look execut come year restructur globu medic inc class execut year vs easi comp us emerg tech provid multipl oppti upsid guidanc clear path growth new product matur sale forc drive upsid execut stori upon fda approv new manufactur facil pricepric targetmkt cap p/eev/salesgmcurr thoughtsdexcom near-term impact competit nois strong pipelin close/surpass competit fundament heel competitor consolid ou opportun new product cycl nxstage medic acquisit freseniu medic care ent grow pain behind investor look si buy weaknessentellu medic acquisit pricepric targetmkt cap p/eev/salesgmcurr thoughtssenseon hold approv loom horizon may adcom panel roch invest rais lot eyebrow obalon therapeut market oppti think execut bring investor sidelin pricepric targetmkt cap p/eev/salesgmcurr thoughtshistogen trial fulli enrol time wait see data robot reimburs polici key acceler growth pricepric targetmkt cap p/eev/salesgmcurr thoughtszimm biomet hold cheap top-lin growth om pressur share rang bound conformi sign management made right investments/chang recharg commercializationjanuari cap larg mid cap peak/trough multipl forward price-to-earnings multipl small cap peak/trough multipl forward ev/sal multiplessourc compani report canaccord genuiti estim factset past perform predict futur result brandon vazquez canaccord genuiti inc us med-tech valuat current historichistor p/ekey narr coverag shift valu outpatientkyl canaccord genuiti inc us environ increas cost/pric headwind hospit payer procedur normal reserv inpati set shift less acut set outpati whenev possibl due varieti factor includ reimburs risk/benefit procedur techniqu improv medic technolog still minor specif patient gener younger healthier physician high-volum highly-skil provid hospit system vertic integr comprehens pre/post op capabl implant system believ help drive shift come yr intuit may revolution gener surgeri da vinci past emerg robot assist surgeri start take hold orthoped mako total knee launch underway expect materi new product launch next year across orthoped spine joint replac key focu player includ snn peopl live diabet us alon date improv comput power person technolog provid opportun empow diabet patient whose treatment requir constant analysi insulin dose carbohydr intak subsequ impact blood glucos level comprehens view individu patient data lead better treatment prescript trend util decision-mak standpoint patient provid payer medic devic sector januari would put new money work compound-annual-growth-rate compound-annual-growth-rate done wait pullback despit rich valuat think strong season mention tax reform sustain sector momenum near-term think smid cap name exposur tax reform focu investor start space mean year mindsetexpect remain major theme long-term help support small-cap valuat particularli current levelsstay patient refin shop list favorit pullback buy list sienne posit discern chang fundament get connectivity/analyt diabet compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate rise machinesaddit buy-rat name compound-annual-growth-rate compound-annual-growth-rate compani current valuat may balanc risk/reward compound-annual-growth-rate name upcom catalyst compound-annual-growth-rate compound-annual-growth-rate comp tabl medic technolog larg cap billion
biomed devic servic
 dickinson surgic scientif biomet hold lifesci technolog nephew plc sponsor sirona schein laboratori diagnost compani medic system exclud market cap billion million except per share data medic devic universeev/ebitdarev compound-annual-growth-rate salesep compound-annual-growth-rate revenuesci epsp/ ratioev/sal comp tabl medic technolog mid cap billion
biomed devic servic
salescompani hold medic medic inc class lifesci hold medic group medic system exclud devic universemid market cap billion billion million except per share enuesci epsev/salesp/ ratioev/ebitdap/e/g compound-annual-growth-rate compound-annual-growth-rate comp tabl medic technolog small cap
biomed devic servic
salescompani group hold robot ltd sponsor medic ent system group hold surgic vascular medic system technolog hold exclud devic universesmal market cap billion million million except per share enuesci epsev/salesp/ ratioev/ebitdap/e/g compound-annual-growth-rate compound-annual-growth-rate comp tabl medic technolog high growth
biomed devic servic
technolog robot ltd sponsor ent system technolog exclud devic high growth million except per share data price-to-earnings ratioev/ebitdarev compound-annual-growth-rate salesep compound-annual-growth-rate revenuesci epsp/e/g short interest tabl medic technolog
biomed devic servic
 capmid capsmal cap cg estim rel consensu
biomed devic servic
kyle canaccord genuityestim incdexcom inc entellu ical inc cfmscanaccord genuityconsensusdxcmcanaccord genuityconsensusentlcanaccord ical inc class ahistogen corp insulet corporationgmedcanaccord genuityconsensushsgxcanaccord genuityconsensuspoddcanaccord ent incnuvas inc nxstage ical inc xentcanaccord genuityconsensusnuvacanaccord genuityconsensusnxtmcanaccord inc rewalk robot ltd senseon hold inc oblncanaccord genuityconsensusrwlkcanaccord genuityconsensussenscanaccord incsmith nephewstryk corporationsiencanaccord genuityconsensussnncanaccord genuityconsensussykcanaccord biomet hold inc zbhcanaccord valuat small mid larg cap near high
biomed devic servic
octob mean exclud high high- mean exclud high mean exclud high valuat mean exclud high decad high mean exclud high valuat mean exclud high histor valuat matter smid-cap med-tech multipl revenu growth gross margin
biomed devic servic
angoanikatrcbeatcsiicnmdcrycutrdxcmentlghdxgkosgmedhaehrcingnpodditgriartxentirtcktwolmatlivnmasimmsinvronuvanxtmosurofixpenstaatcmdwmgiy gross margin revenu growth med-tech regress analysi -market cap rang biomed devic servic
